Opinion
Video
Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma
Author(s):
Experts discuss a preference for ipilimumab/nivolumab as the frontline immunotherapy for patients with BRAF-mutant metastatic melanoma given its proven long-term efficacy but acknowledge nivolumab/relatlimab as an option with less toxicity, especially adrenal insufficiency.
Related Videos
Related Content
